383 related articles for article (PubMed ID: 27707674)
1. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N; Nguyen-Khoa T; Alyanakian MA
Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
5. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
7. Serum-free light-chain assay: clinical utility and limitations.
Bhole MV; Sadler R; Ramasamy K
Ann Clin Biochem; 2014 Sep; 51(Pt 5):528-42. PubMed ID: 24489083
[TBL] [Abstract][Full Text] [Related]
8. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
Mayo MM; Johns GS
Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
[TBL] [Abstract][Full Text] [Related]
9. [The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies].
Ščudla V; Pika T; Minařík J
Vnitr Lek; 2015 Jan; 61(1):60-1, 63-71. PubMed ID: 25693618
[TBL] [Abstract][Full Text] [Related]
10. [Free light chains assay: Indications and methods].
Martellosio JP; Leleu X; Roblot P; Martin M; Puyade M
Rev Med Interne; 2019 May; 40(5):297-305. PubMed ID: 30862366
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies].
Lakomy D; Lemaire-Ewing S; Denimal D; Bastie JN; Lafon I; Caillot D
Ann Biol Clin (Paris); 2013; 71(2):157-63. PubMed ID: 23587579
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
[TBL] [Abstract][Full Text] [Related]
14. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
15. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of free light chain measurement in monoclonal gammopathy, other haematological malignancies and autoimmune diseases].
Verebi C; Talbot A; Gendron N; Hurtado-Nedelec M
Ann Biol Clin (Paris); 2019 Aug; 77(4):397-406. PubMed ID: 31418701
[TBL] [Abstract][Full Text] [Related]
17. [Determination of light chains in serum].
Hansen CT; Nielsen L; Münster AM; Abildgaard N
Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
[TBL] [Abstract][Full Text] [Related]
18. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Hevylite™ IgA and IgG assay with conventional techniques for the diagnosis and follow-up of plasma cell dyscrasia.
Paolini L; Di Noto G; Maffina F; Martellosio G; Radeghieri A; Luigi C; Ricotta D
Ann Clin Biochem; 2015 May; 52(Pt 3):337-45. PubMed ID: 25468997
[TBL] [Abstract][Full Text] [Related]
20. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]